#USA #BioLife Solutions #Bothell #Cell Therapy #Bioprocessing

BioLife Solutions Reports Strong Financial Growth for Q2 2025

BioLife Solutions, Inc. (Nasdaq: BLFS), a prominent player in the development and supply of cell processing tools and services geared towards the cell and gene therapy market, has released its financial report for the second quarter of 2025, highlighting a robust growth trajectory.

Impressive Revenue Growth

For the second quarter, the company achieved a remarkable cell processing revenue of $23 million, reflecting a striking 28% increase compared to the same period last year. This marks the company’s seventh consecutive quarter of sequential revenue growth, underscoring the strength and reliability of their product lineup.

The overall revenue for Q2 2025 reached $25.4 million, an increase of 29% from $19.7 million in Q2 2024. The growth in revenue has been significantly driven by the biopreservation media (BPM) franchise, which has demonstrated consistent performance across both direct and distribution channels. Notably, approximately 40% of total BPM revenue stemmed from customers with approved commercial therapies, signifying the embedded trust of BioLife products in successful clinical outcomes.

Financial Metrics

Despite the revenue growth, BioLife reported a net loss of $15.8 million for the second quarter, which included a one-time, non-cash charge of $15.5 million for an in-process research and development (IPRD) expense incurred from the acquisition of PanTHERA CryoSolutions, Inc. Adjusted EBITDA for the quarter amounted to $6.1 million, or 24% of revenue, showcasing operational efficiency.

In light of the strong performance in Q2, the company has raised its full-year revenue guidance to a range of $100 million to $103 million, up from the previous estimate of $95.5 million to $99 million. They now expect cell processing revenue to hit between $91 million to $93 million, illustrating confidence in their growth strategy moving forward.

Business Developments

Several key developments have underpinned BioLife’s success this quarter:

• - Their biopreservation media is featured in over 250 ongoing, commercially-sponsored clinical trials across the U.S., claiming more than 70% market share.
• - The biopreservation media is now embedded in 16 unique commercial cell and gene therapies, with expectations of 10 additional approvals within the next year.
• - The acquisition of PanTHERA, a company known for innovative cryopreservation technology, has fortified BioLife’s position in the biopreservation market.
• - Recent investments, including a $2 million purchase of convertible notes in Pluristyx, Inc., further bolstered their range of capabilities in stem cell-based products.

Outlook and Market Position

BioLife Solutions demonstrates resilience and growth potential, even amidst uncertain macroeconomic conditions. Their strategic focus on creating operational efficiencies and maintaining a streamlined product lineup positions them well for sustained growth. The management's commentary indicates a positive outlook for the second half of 2025, with expectations of continued revenue expansion and improved gross margin percentages.

The company set itself apart as a trusted partner for clinical programs at all trial phases, particularly in late-stage trials where the likelihood of commercial success is greatest. This strategic positioning is crucial for BioLife Solutions as they continue to invest in research and development while expanding their market presence and technological capabilities.

In summary, BioLife Solutions is not just navigating the competitive landscape of the cell and gene therapy market but thriving in it, presenting ample opportunities for future growth. As the company continues to evolve, it will be interesting to see how they leverage their expertise and partnerships to provide innovative solutions that will aid in the advancement of therapies that significantly impact patient care.